US Reclassifies Medical Marijuana to Schedule III, Easing Tax Burden for Cannabis Firms

The Trump administration has officially reclassified medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. This shift places medical cannabis alongside regulated drugs with recognized medical utility, such as testosterone, moving it away from the category containing heroin, which is viewed as having no medical use. The primary driver for investor optimism is the removal of the 280E tax penalty. Under Schedule I, cannabis firms were prohibited from claiming standard business deductions, a headwind that severely constrained earnings and free cash flow. By moving to Schedule III, operators can now utilize normal business deductions, which analysts expect will lead to healthier balance sheets. The U.S. Drug Enforcement Administration is scheduled to hold a hearing on June 29 to determine if this Schedule III status should be extended to all cannabis products, including those for recreational use. Such a move would further expand the financial benefits for the industry. Market reaction was immediate, with shares of prominent firms including Tilray, Canopy Growth, and Curaleaf recording double-digit gains. Industry leaders suggest that this is the first major step toward making the sector more investable, potentially paving the way for acceptance by major banks and brokerages. However, significant hurdles remain. Cannabis remains federally illegal, and the industry faces continued political opposition, notably from House Speaker Mike Johnson. Until full federal clarity is provided, the sector remains sensitive to regulatory shifts and political sentiment.